全球重组蛋白治疗药物开发和生产组织（CDMO）市场规模、份额、趋势和成长分析报告（2026-2034）

预计重组蛋白疗法 CDMO 市场将从 2025 年的 313.5 亿美元成长到 2034 年的 1,036.5 亿美元，2026 年至 2034 年的复合年增长率为 14.21%。

受生物製药和生物相似药需求不断增长的推动，全球重组蛋白疗法（CDMO）市场正经历强劲成长。製药公司将生产外包给CDMO，以降低成本并缩短产品上市时间。慢性病盛行率的上升也显着增加了对蛋白质疗法的需求。

关键成长要素包括生物製程技术的进步、生物技术产业的扩张以及生物製药监管核准的增加。单株抗体和标靶治疗的日益普及也增强了市场需求。此外，合约研发生产机构（CDMO）透过提供可扩展的生产能力，吸引了新兴生物技术公司和成熟的製药公司。

展望未来，细胞株开发和连续生产过程的创新可望惠及市场。生物製剂产品线的拓展和生物製药研发投入的增加将进一步推动市场成长。新兴市场预计将在扩大产能和确保可持续的长期成长方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球重组蛋白治疗药物开发与生产组织（CDMO）市场：依类型划分

• 市场分析、洞察与预测
• 生长激素
• 干扰素
• 疫苗
• 免疫刺激剂
• 其他的

第五章：全球重组蛋白治疗药物开发与生产组织（CDMO）市场：依来源划分

• 市场分析、洞察与预测
• 哺乳动物系统
• 微生物系统
• 其他的

第六章：全球重组蛋白治疗药物（CDMO）市场：依适应症划分

• 市场分析、洞察与预测
• 肿瘤学
• 感染疾病
• 免疫疾病
• 代谢性疾病
• 血液疾病
• 其他的

第七章 全球重组蛋白治疗药物开发与生产组织（CDMO）市场：依服务类型划分

• 市场分析、洞察与预测
• 契约製造
• 合约开发

第八章：全球重组蛋白治疗药物开发与生产组织（CDMO）市场：依最终用途划分

• 市场分析、洞察与预测
• 製药公司
• 生技公司
• 其他的

第九章 全球重组蛋白治疗药物研发生产机构（CDMO）市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Richter-Helm BioLogics
  • Lonza
  • Catalent Inc
  • Fujifilm Diosynth Biotechnologies
  • WuXi Biologics
  • Curia Global Inc
  • Batavia Biosciences BV
  • HALIX BV
  • Biovian
  • Enzene Biosciences Ltd

The Recombinant Protein Therapeutics CDMO Market size is expected to reach USD 103.65 Billion in 2034 from USD 31.35 Billion (2025) growing at a CAGR of 14.21% during 2026-2034.

The Global Recombinant Protein Therapeutics CDMO Market is experiencing strong growth driven by increasing demand for biologics and biosimilars. Pharmaceutical companies are outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) to reduce costs and accelerate time-to-market. Rising prevalence of chronic diseases has significantly increased demand for protein-based therapeutics.

Major growth drivers include advancements in bioprocessing technologies, expanding biotechnology sector, and increasing regulatory approvals for biologic drugs. The growing focus on monoclonal antibodies and targeted therapies has strengthened market demand. Additionally, CDMOs offer scalable production capabilities, attracting both emerging biotech firms and established pharmaceutical companies.

Looking forward, the market is expected to benefit from innovations in cell line development and continuous manufacturing processes. Expansion of biologics pipelines and increasing investments in biopharmaceutical research will further drive growth. Emerging markets are likely to play a crucial role in expanding manufacturing capacities, ensuring sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Growth Hormones
• Interferons
• Vaccines
• Immunostimulating Agents
• Others

By Source

• Mammalian Systems
• Microbial Systems
• Others

By Indication

• Oncology
• Infectious Diseases
• Immunological Disorders
• Metabolic Disorders
• Haematological Disorders
• Others

By Service Type

• Contract Manufacturing
• Contract Development

By End Use

• Pharmaceutical Companies
• Biotech Companies
• Others

COMPANIES PROFILED

• RichterHelm BioLogics, Lonza, Catalent Inc, Fujifilm Diosynth Biotechnologies, WuXi Biologics, Curia Global Inc, Batavia Biosciences BV, HALIX BV, Biovian, Enzene Biosciences Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Growth Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunostimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Mammalian Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Microbial Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Haematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Service Type
• 7.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Source
  • 9.2.3 By Indication
  • 9.2.4 By Service Type
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Source
  • 9.3.3 By Indication
  • 9.3.4 By Service Type
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Source
  • 9.4.3 By Indication
  • 9.4.4 By Service Type
  • 9.4.5 By End Use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Source
  • 9.5.3 By Indication
  • 9.5.4 By Service Type
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Source
  • 9.6.3 By Indication
  • 9.6.4 By Service Type
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Richter-Helm BioLogics
  • 11.2.2 Lonza
  • 11.2.3 Catalent Inc
  • 11.2.4 Fujifilm Diosynth Biotechnologies
  • 11.2.5 WuXi Biologics
  • 11.2.6 Curia Global Inc
  • 11.2.7 Batavia Biosciences B.V
  • 11.2.8 HALIX B.V
  • 11.2.9 Biovian
  • 11.2.10 Enzene Biosciences Ltd